Physician profile

Ronald A Cohen

Cardiovascular Disease · Haddon Heights, NJ

NPI 1144273509

$7,772.21

in general payments reported to CMS, 2019-2025

35 companies · $1,125 in 2025

The $1,125 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

See the full distribution for Cardiovascular Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,896.80
Education$19.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,285.00 2019-2025
Janssen Pharmaceuticals, INC $837.51 2019-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $833.03 2019-2025 Lifevest
Impulse Dynamics (USA) INC. $776.38 2022-2025 Optimizer, Optimizer
Pfizer INC. $569.94 2019-2025
Amgen INC. $519.44 2019-2025 Repatha, Repatha
Amarin Pharma, INC. $378.11 2019-2021
Merck Sharp & Dohme LLC $280.71 2021-2024 Verquvo
Bayer Healthcare Pharmaceuticals INC. $216.81 2021-2025
Abbott Laboratories $206.09 2020-2025 Perclose Prostyle, Aveir, Navitor
Sanofi-Aventis U.S. LLC $198.46 2019-2023
E.R. Squibb & Sons, L.L.C. $190.71 2019-2025 Eliquis, Camzyos
Novo Nordisk INC $173.14 2021-2024 Wegovy, Ozempic, Rybelsus
W. L. Gore & Associates, INC. $171.46 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $168.27 2023-2025 Jardiance
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $153.33 2019-2024 Wainua, Farxiga
Esperion Therapeutics, INC. $115.85 2020-2025 Nexletol
Boston Scientific Corporation $95.99 2019-2024 Watchman Flx
Regeneron Healthcare Solutions, INC. $94.19 2019
Kowa Pharmaceuticals America, INC. $90.45 2019-2022
Cvrx, INC. $67.98 2024 Barostim Neo System
Daiichi Sankyo INC. $45.41 2023-2024 Injectafer
Astellas Pharma US INC $40.74 2019
Scpharmaceuticals INC. $38.49 2023-2025
Philips North America LLC $35.19 2023-2024 (5044) Mcot
Actelion Pharmaceuticals US, INC. $31.18 2023 Uptravi, Opsumit
Lundbeck LLC $26.13 2019-2020
Inspire Medical Systems, INC. $20.07 2024 Inspire
Cardiovascular Systems INC. $19.63 2023 Diamondback Peripheral
Heartflow, INC. $17.47 2024
Elutia, INC. $17.11 2021
Regeneron Pharmaceuticals, INC. $16.80 2019
Kiniksa Pharmaceuticals International, Plc $14.09 2024 Arcalyst
Kiniksa Pharmaceuticals, LTD. $13.88 2023 Arcalyst
Otsuka America Pharmaceutical, INC. $13.17 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ronald A Cohen

$7,772.21

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $1,125 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/51883/ronald-a-cohen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.